Drug intelligence / Profile preview

Alba

Development stage: Unknown
Lead developer: OMNIFARMA
Administration: Oral

Overview

Alba is a dietary supplement developed by Omnifarma (Kiev, Ukraine) containing a standardized dry extract of the roots and rhizomes of white cinquefoil (*Potentilla alba*). It is primarily used to normalize thyroid function in patients with various thyroid disorders, including hyperthyroidism, hypothyroidism, autoimmune thyroiditis, and endemic goiter. The extract is rich in flavonoids, phenolics, and essential trace elements such as iodine, selenium, zinc, and magnesium. Its mechanism of action is attributed to the synergistic effect of these components, which help regulate thyroid hormone levels, provide antioxidant protection to thyroid tissue, and support the overall endocrine system. Alba is typically administered orally in capsule form.

Brand names: AlbaАльба
Other names: white cinquefoil extractPotentilla alba extract

Beyond the preview

Go deeper on Alba.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alba.

Explore the full profile